Article

Interpretación de las pruebas de laboratorio habituales en las enfermedades reumatológicas inflamatorias

EMC - Tratado de Medicina 01/2006; 10(1):1–9. DOI: 10.1016/S1636-5410(06)70375-0

ABSTRACT Resulta difícil identificar la causa de las poliartritis en fase inicial, y no existe un acuerdo sobre las pruebas de laboratorio o radiológicas que se deben realizar en estos casos. Al revisar la literatura reciente, se ha podido comprobar que los artículos relativos a este tema, con cohortes de reumatismos en fase inicial, son menos de 30, y tratan sobre todo los factores reumatoideos, los anticuerpos anticitrulina y la tipificación del antígeno HLA. Una encuesta de opinión demuestra que, aunque existen grandes variaciones, las pruebas de laboratorio que se prescriben en las fases iniciales de los reumatismos inflamatorios son limitadas (NFS, VSG, CRP, fibrina, creatinina, ASAT, ALAT, proteinuria, hierro, CPK, serología de hepatitis B, de hepatitis C y de Lyme, TCA, anticuerpos antinucleares, factores reumatoideos, anticuerpos antiqueratina o anti-CCP y HLA B27). Una vez establecido el diagnóstico, el laboratorio sigue siendo esencial para la detección de afecciones viscerales y para el seguimiento de la inflamación.

0 Bookmarks
 · 
62 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate whether the determination of serum procalcitonin (PCT) in systemic autoimmune disease will help to discriminate invasive infection from highly active underlying disease. Three hundred ninety-seven serum samples, from 18 patients with systemic lupus erythematosus (SLE) and 35 patients with systemic antineutrophil cytoplasmic antibody-associated vasculitis (AAV), were analyzed. Clinical disease activity was assessed by the Systemic Lupus Activity Measure in SLE patients and by the Birmingham Vasculitis Activity Score in AAV patients. Procalcitonin concentrations were determined in parallel with concentrations of neopterin, interleukin-6 (IL-6), and C-reactive protein (CRP). Additionally, serum creatinine values were obtained. In 321 of the 324 samples from the 42 patients with autoimmune disease but without systemic infection, serum PCT levels were within the normal range (i.e., <0.5 ng/ml), whereas the values for neopterin, IL-6, and CRP were elevated in patients with active underlying disease. All 16 systemic infections occurred in 11 patients with AAV, and were associated with PCT levels that were markedly elevated, to a mean +/- SD of 1.93 +/- 1.19 ng/ml. No correlation between the degree of renal impairment and PCT concentrations was seen. PCT may serve as a useful marker for the detection of systemic bacterial infection in patients with systemic autoimmune disease.
    Arthritis & Rheumatology 07/1997; 40(7):1250-6. DOI:10.1002/1529-0131(199707)40:7<1250::AID-ART9>3.0.CO;2-A · 7.87 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Trials of rheumatoid arthritis (RA) treatments report the average response in multiple outcome measures for treated patients. It is more clinically relevant to test whether individual patients improve with treatment, and this identifies a single primary efficacy measure. Multiple definitions of improvement are currently in use in different trials. The goal of this study was to promulgate a single definition for use in RA trials. Using the American College of Rheumatology (ACR) core set of outcome measures for RA trials, we tested 40 different definitions of improvement, using a 3-step process. First, we performed a survey of rheumatologists, using actual patient cases from trials, to evaluate which definitions corresponded best to rheumatologists' impressions of improvement, eliminating most candidate definitions of improvement. Second, we tested 20 remaining definitions to determine which maximally discriminated effective treatment from placebo treatment and also minimized placebo response rates. With 8 candidate definitions of improvement remaining, we tested to see which were easiest to use and were best in accord with rheumatologists' impressions of improvement. The following definition of improvement was selected: 20% improvement in tender and swollen joint counts and 20% improvement in 3 of the 5 remaining ACR core set measures: patient and physician global assessments, pain, disability, and an acute-phase reactant. Additional validation of this definition was carried out in a comparative trial, and the results suggest that the definition is statistically powerful and does not identify a large percentage of placebo-treated patients as being improved. We present a definition of improvement which we hope will be used widely in RA trials.
    Arthritis & Rheumatology 07/1995; 38(6):727-35. · 7.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We have attempted to design classification criteria for adult Still's disease by analyzing the data obtained through a multicenter survey of 90 Japanese patients with this disease and of 267 control patients. The proposed criteria consisted of fever, arthralgia, typical rash, and leukocytosis as major, and sore throat, lymphadenopathy and/or splenomegaly, liver dysfunction, and the absence of rheumatoid factor and antinuclear antibody as minor criteria. Requiring 5 or more criteria including 2 or more major criteria yielded 96.2% sensitivity and 92.1% specificity. However, an exclusion process will be needed for an accurate classification, since this disease is relatively rare.
    The Journal of Rheumatology 04/1992; 19(3):424-30. · 3.17 Impact Factor